The landscape for stage IV driver mutation-negative NSCLC is shifting toward even greater precision. ASCO has released critical updates to the Living Guidelines, emphasizing that the “absence” of a driver mutation is a vital biomarker in itself.

An interview with Joshua Reuss, MD, thoracic medical oncologist at Georgetown University and co-author of the guidelines.